Intra-arterial Stem Cell Therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a

Vats, Kanchan; Sarmah, Deepaneeta; Datta, Aishika; Saraf, Jackson; Kaur, Harpreet; Pravalika, Kanta; Wanve, Madhuri; Kalia, Kiran; Borah, Anupom; Dave, Kunjan R.; Yavagal, Dileep R.; Bhattacharya, Pallab

doi:10.1007/s12031-019-01460-3

Cited by 19 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in the animal model of IS, researchers also confirmed that MSCs can reduce the levels of proinflammatory cytokines TNF-α and IL-1β and reduce the infarct volume after focal cerebral ischemia [31]. Studies have shown that intra-arterial application of MSCs can inhibit the activation of acid sensing ion channels (ASICs) and then decrease the expression of the inflammasome, which leads to the inhibition of the activation of IL-1β [32]. Liu et al reported that transplanted MSCs could alleviate nerve injury after focal cerebral ischemia by upregulating the expression of antiinflammatory cytokine IL-10 and downregulating the expression of proinflammatory cytokine TNF-α [33].…”

Section: Mechanism Of Mscs In the Treatment Of Ismentioning

confidence: 86%

Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke

Guo

Peng

Zeng

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

Ischemic stroke (IS) is a serious cerebrovascular disease with high morbidity and disability worldwide. Despite the great efforts that have been made, the prognosis of patients with IS remains unsatisfactory. Notably, recent studies indicated that mesenchymal stem cell (MSCs) therapy is becoming a novel research hotspot with large potential in treating multiple human diseases including IS. The current article is aimed at reviewing the progress of MSC treatment on IS. The mechanism of MSCs in the treatment of IS involved with immune regulation, neuroprotection, angiogenesis, and neural circuit reconstruction. In addition, nutritional cytokines, mitochondria, and extracellular vesicles (EVs) may be the main mediators of the therapeutic effect of MSCs. Transplantation of MSCs-derived EVs (MSCs-EVs) affords a better neuroprotective against IS when compared with transplantation of MSCs alone. MSC therapy can prolong the treatment time window of ischemic stroke, and early administration within 7 days after stroke may be the best treatment opportunity. The deliver routine consists of intraventricular, intravascular, intranasal, and intraperitoneal. Furthermore, several methods such as hypoxic preconditioning and gene technology could increase the homing and survival ability of MSCs after transplantation. In addition, MSCs combined with some drugs or physical therapy measures also show better neurological improvement. These data supported the notion that MSC therapy might be a promising therapeutic strategy for IS. And the application of new technology will promote MSC therapy of IS.

show abstract

Section: Mechanism Of Mscs In the Treatment Of Ismentioning

confidence: 86%

Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke

Guo

Peng

Zeng

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Furthermore, in a more recent oxygen-glucose deprivation study in hippocampal slices from mice, amiloride failed to lead to significant neuroprotection [28]. [8,17,18,21,24,26,32] or hypoxia induced by reducing blood pressure via mechanical compression of the aorta (right) [27].…”

Section: Trends In Pharmacological Sciencesmentioning

confidence: 99%

“…(B) Stroke severity is typically assessed via brain slices and subsequent histochemistry (left) [8,17,18,21,24,26,27,32] and/or observations of motor function and behavior (right) [21,24,32]. Created using BioRender.com.…”

Section: Trends In Pharmacological Sciencesmentioning

confidence: 99%

“…In conclusion, there is now ample evidence that ASICs are involved in the pathophysiology of ischemic stroke and that a variety of ASIC1a-targeting approaches appear promising, including inhibition of ASIC1a via peptide toxins such as Hi1a, antibodies, or targeted disruption of protein-protein interactions. However, further studies are needed to determine the most viable therapeutic avenue, potentially including exploration of non-pharmacological interventions, such as stem cell therapy [32].…”

Section: Disruption Of Protein-protein Interactionsmentioning

confidence: 99%

“…Examples of stroke models and assessment criteria. (A) Common stroke models: middle cerebral artery occlusion (MCAO) induced via local occlusion of the artery or infusion of endothein-1 via a cannula (left)[8,17,18,21,24,26,32] or hypoxia induced by reducing blood pressure via mechanical compression of the aorta (right)[27]. (B) Stroke severity is typically assessed via brain slices and subsequent histochemistry (left)[8,17,18,21,24,26,27,32] and/or observations of motor function and behavior (right)[21,24,32].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Acid-sensing ion channels as potential therapeutic targets

Heusser

Pless

2021

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) and MSC‐derived exosomes in animal models of central nervous system diseases: Targeting the NLRP3 inflammasome

et al. 2023

View full text Add to dashboard Cite

The NLRP3 (NOD‐, LRR‐, and pyrin domain‐containing protein 3) inflammasome is a multimeric protein complex that is engaged in the innate immune system and plays a vital role in inflammatory reactions. Activation of the NLRP3 inflammasome and subsequent release of proinflammatory cytokines can be triggered by microbial infection or cellular injury. The NLRP3 inflammasome has been implicated in the pathogenesis of many disorders affecting the central nervous system (CNS), ranging from stroke, traumatic brain injury, and spinal cord injury to Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and depression. Furthermore, emerging evidence has suggested that mesenchymal stem cells (MSCs) and their exosomes may modulate NLRP3 inflammasome activation in a way that might be promising for the therapeutic management of CNS diseases. In the present review, particular focus is placed on highlighting and discussing recent scientific evidence regarding the regulatory effects of MSC‐based therapies on the NLRP3 inflammasome activation and their potential to counteract proinflammatory responses and pyroptotic cell death in the CNS, thereby achieving neuroprotective impacts and improvement in behavioral impairments.

show abstract

Intra-arterial Stem Cell Therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a

Cited by 19 publications

References 28 publications

Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke

Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke

Acid-sensing ion channels as potential therapeutic targets

Mesenchymal stem cells (MSCs) and MSC‐derived exosomes in animal models of central nervous system diseases: Targeting the NLRP3 inflammasome

Contact Info

Product

Resources

About